Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer

被引:17
作者
Hartung, G
Hofheinz, RD
Wein, A
Riedel, C
Rost, A
Fritze, D
Kreuser, ED
Drees, M
Kühnel, J
Hehlmann, R
Queisser, W
机构
[1] Univ Klinikum Rostock, Hamatol Onkol Abt, Klin & Poliklin Innere Med, D-18057 Rostock, Germany
[2] Univ Heidelberg, Onkol Zentrum, Med Klin 3, Univ Klinikum Mannheim, Mannheim, Germany
[3] Univ Erlangen Nurnberg, Med Klin 1, D-8520 Erlangen, Germany
[4] Klinikum Darmstadt, Med Klin 5, Darmstadt, Germany
[5] Krankenhaus Barmherzigen Bruder, Med Klin, Regensburg, Germany
[6] Medac GMBH, Wedel, Germany
来源
ONKOLOGIE | 2001年 / 24卷 / 05期
关键词
colorectal cancer; phase II study; 5-fluorouracil; calcium-folinic acid; sodium-folinic acid; weekly 24-hour infusion;
D O I
10.1159/000055126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous Lv. administration in combination with 5-FU in one pump. Patients and Methods; From 1997 to 1998, 51 patients [median age 60 (range 24-77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3-54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% Cl: 5.8-11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%Cl: 10.2-22.8). Among major toxicities, NCL-CTC grade III/IV diarrhea occurred in 13/51 25.4%), grade III hand-foot syndrome in 6/51 (11.7% patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.
引用
收藏
页码:457 / 462
页数:8
相关论文
共 22 条
[1]   A PHASE-II STUDY OF WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE FLUOROURACIL WITH LEUCOVORIN IN COLORECTAL-CARCINOMA [J].
ARDALAN, B ;
CHUA, L ;
TIAN, EM ;
REDDY, R ;
SRIDHAR, K ;
BENEDETTO, P ;
RICHMAN, S ;
LEGASPI, A ;
WALDMAN, S ;
MORRELL, L ;
FEUN, L ;
SAVARAJ, N ;
LIVINGSTONE, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :625-630
[2]  
BOARMAN DM, 1992, CANCER RES, V52, P36
[3]   New drugs in colorectal cancer: A review of antitumor activity and cross-resistance patterns of topoisomerase I inhibitors, thymidylate synthetase inhibitors, and oxaliplatin [J].
Harstrick, A ;
Vanhoefer, U ;
Seeber, S .
ONKOLOGIE, 1998, 21 (02) :95-103
[4]   Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer?: A phase II study [J].
Hartmann, JT ;
Köhne, CH ;
Schmoll, HJ ;
Daikeler, T ;
Kanz, L ;
Bokemeyer, C .
ONCOLOGY, 1998, 55 (04) :320-325
[5]   Combination of bolus 5-fluorouracil, folinic acid and mitomycin C in advanced gastric cancer:: Results of a phase II trial [J].
Hartung, G ;
Hofheinz, R ;
Buchheidt, D ;
Rost, A ;
Brecht, A ;
Forche, K ;
Schröder, M ;
Wojatschek, C ;
Fritze, D ;
Hehlmann, R ;
Queisser, W .
ONKOLOGIE, 2000, 23 (05) :444-447
[6]   FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS [J].
HEIDELBERGER, C ;
CHAUDHURI, NK ;
DANNEBERG, P ;
MOOREN, D ;
GRIESBACH, L ;
DUSCHINSKY, R ;
SCHNITZER, RJ ;
PLEVEN, E ;
SCHEINER, J .
NATURE, 1957, 179 (4561) :663-666
[7]  
HOUGHTON JA, 1990, CANCER RES, V50, P3940
[8]   HIGH-DOSE 5-FLUOROURACIL (5-FU) AND FOLINIC ACID IN ADVANCED COLORECTAL SITES OF DISEASE CANCER RESISTANT TO STANDARD-DOSE LOCAL 5-FU TREATMENT - RESULTS OF A LIVER PHASE-II STUDY [J].
JAGER, E ;
KLEIN, O ;
WACHTER, B ;
MULLER, B ;
BRAUN, U ;
KNUTH, A .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) :1717-1717
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]   Advanced colorectal cancer: Which regimes should we recommend? [J].
Koehne, CH ;
Midgley, R ;
Seymour, M ;
Kerr, DJ .
ANNALS OF ONCOLOGY, 1999, 10 (08) :877-882